ArticleNanomedicine (London, England)2012
Chemotherapy targeting by DNA capture in viral protein particles.
Article in Nanomedicine (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Nano-bioparticles: Fighting cancer with targeted nanotherapy.Open access government · 2026Article
- Systemic HER3 ligand-mimicking nanobioparticles enter the brain and reduce intracranial tumour growth.Nature nanotechnology · 2025Article
- Review
- Biomedical Applications of Translational Optical Imaging: From Molecules to Humans.Molecules (Basel, Switzerland) · 2021Review
- Cell Membrane-Based Biomimetic Nanoparticles and the Immune System: Immunomodulatory Interactions to Therapeutic Applications.Frontiers in bioengineering and biotechnology · 2020Review
- HER3-targeted protein chimera forms endosomolytic capsomeres and self-assembles into stealth nucleocapsids for systemic tumor homing of RNA interference in vivo.Nucleic acids research · 2019Article
- Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Biomimetic strategies for targeted nanoparticle delivery.Bioengineering & translational medicine · 2016Review
- A corrole nanobiologic elicits tissue-activated MRI contrast enhancement and tumor-targeted toxicity.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
- Integrative nanomedicine: treating cancer with nanoscale natural products.Global advances in health and medicine · 2014Review
- Analysis of targeted viral protein nanoparticles delivered to HER2+ tumors.Journal of visualized experiments : JoVE · 2013Article
- Development of adenovirus capsid proteins for targeted therapeutic delivery.Therapeutic delivery · 2013Review
- Photoexcitation of tumor-targeted corroles induces singlet oxygen-mediated augmentation of cytotoxicity.Journal of controlled release : official journal of the Controlled Release Society · 2012Article
- Multimodality imaging in vivo for preclinical assessment of tumor-targeted doxorubicin nanoparticles.PloS one · 2012Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
Abstract
aimThis study tests the hypothesis that DNA intercalation and electrophilic interactions can be exploited to noncovalently assemble doxorubicin in a viral protein nanoparticle designed to target and penetrate tumor cells through ligand-directed delivery. We further test whether this new paradigm of doxorubicin targeting shows therapeutic efficacy and safety in vitro and in vivo. MATERIALS &
methodsWe tested serum stability, tumor targeting and therapeutic efficacy in vitro and in vivo using biochemical, microscopy and cytotoxicity assays.
resultsSelf-assembly formed approximately 10-nm diameter serum-stable nanoparticles that can target and ablate HER2+ tumors at >10× lower dose compared with untargeted doxorubicin, while sparing the heart after intravenous delivery. The targeted nanoparticle tested here allows doxorubicin potency to remain unaltered during assembly, transport and release into target cells,while avoiding peripheral tissue damage and enabling lower, and thus safer, drug dose for tumor killing.
conclusionThis nanoparticle may be an improved alternative to chemical conjugates and signal-blocking antibodies for tumor-targeted treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.